Abstract Library

#4349 Challenging management of ductal adenocarcinoma of the prostate with neuroendocrine differentiation: A case report

Introduction: Ductal adenocarcinoma of the prostate is a rare subtype of prostate cancer that arises from the ducts of the prostate gland. It is characterised by distinct histological features and a more aggressive clinical course. Neuroendocrine differentiation within this subtype is associated with a more aggressive phenotype and can lead to resistance to conventional androgen deprivation therapies.

Conference:

Presenting Author:

Authors: Zerrouk D, Boukerzaza I, Laouar N, Kassama Z, Mansouri F,

Keywords: neuroendocrine prostate cancer, progression, multidisciplinary approach,

#3363 Neuroendocrine prostate cancer: About 4 cases

Introduction: Neuroendocrine tumors of the prostate are rare entities with a very poor prognosis. They can be pure (small or large cell neuroendocrine carcinoma) or mixed. They do not express prostate specific antigen (PSA) or the androgen receptor. Their treatment is based only on chemotherapy based on platinum for the advanced forms.

Conference:

Presenting Author:

Authors: Kehili H, Bengueddache A, Boumansour N, Kaid M, Benabdellah H,

Keywords: neuroendocrine prostate, poor prognosis,

#3016 DLL3 Is Expressed in GEP-Neuroendocrine Neoplasms with Loss of RB1 and Has Prognostic Significance

Introduction: The negative notch regulator DLL3 has gained increasing attention in tumors with neuroendocrine features, in particular SCLC, LCNEC and neuroendocrine prostate cancer, both as prognostic marker and candidate therapeutic target. No data are available on the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liverani C

Authors: Liverani C, Bongiovanni A, Pieri F, Foca F, Ravaioli S,

Keywords: DLL3, RB1, prognostic biomarker, GEP-NEN,

#2142 Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Introduction: Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting delta-like protein 3 (DLL3), an atypical Notch receptor family ligand expressed in high-grade neuroendocrine carcinomas (NECs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Mansfield A

Authors: Mansfield A, Aggarwal R, Beltran H, Farago A, Hann C,

Keywords: Rovalpituzumab tesirine, DLL3, neuroendocrine tumors, antibody-drug conjugate,